For this reason selective activators of VDR (such as paricalcitol) and factors involved in the vitamin D3 axis (as GcMAF) might represent new therapeutic tools both for treatment of CKD and for treatment of chronic conditions where the use of vitamin D3, although potentially beneficial, has been discouraged for the harmful side effects. The gene discussed is VDR; the disease is chronic kidney disease.